Xcout IntelArcutis Biotherapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Arcutis Biotherapeutics, Inc. among biotechnology companies — ranked by similarity to what Arcutis Biotherapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Arcutis Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics is a biotechnology company focused on medical dermatology innovation. The company is publicly traded and dedicated to delivering meaningful treatments in the dermatology field.
Arcutis Biotherapeutics, Inc. at a glance
Arcutis Biotherapeutics, Inc. is a biotechnology company headquartered in Westlake Village, United States. It is publicly listed (ARQT) with a market capitalisation of $3.6B. Xcout tracks 46 named people at Arcutis Biotherapeutics, Inc., including Todd Franklin Watanabe (President, Chief Executive Officer & Director).
Arcutis Biotherapeutics, Inc. leadership
- Todd Franklin WatanabePresident, Chief Executive Officer & Director
- Frank WatanabePresident and CEO
- Latha VairavanSenior Vice President & Chief Financial Officer
- L. Todd EdwardsExecutive Vice President & Chief Commercial Officer
- Patrick E. BurnettExecutive Vice President & Chief Medical Officer
- Masaru MatsudaExecutive VP, Chief Legal Officer & Corporate Secretary
40 more named people on record for Arcutis Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Arcutis Biotherapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Arcutis Biotherapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Similar biotechnology company
Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.
Biotech
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Similar biotechnology company
Aldena Therapeutics is a biotechnology company focused on transforming dermatology through novel siRNA-based treatments for skin conditions.
Biotech
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Biotech
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Biotech
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Similar biotechnology company
Aperta Biosciences is a biopharmaceutical company that develops novel therapeutics for ocular surface diseases, including blepharitis, ocular rosacea, meibomian gland dysfunction, and dry eye disease. The company's lead candidate, APT-001, is an ophthalmic suspension designed to treat the underlying cause of blepharitis by eradicating ocular Demodex infestations.
Similar biotechnology company
NanoBio Corp. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing dermatological products and anti-infective treatments.
Similar biotechnology company
Avere Therapeutics is a biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing oral therapies for the treatment of IL-23-driven inflammatory diseases.
Similar biotechnology company
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Biotech
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Arcutis Biotherapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Arcutis Biotherapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →